US approval of Winlevi in acne is expected by 27 August 2020 (PDUFA date), which will be transformational for Cassiopea and marks the first new mode of action for acne in almost 40 years. Recent market research shows that 90% of US healthcare providers would be extremely likely to prescribe Winlevi.

Read the full Cassiopea Valuation Report

Key catalysts include:

  • Start phase III trials of Breezula in male alopecia (H1 2020)
  • US approval of Winlevi in acne (27 August 2020)
  • Raise funds (Q4 2020)